scholarly journals Recurrent Intestinal Obstruction after Radiation Therapy: A Case Report and Review of the Literature

2019 ◽  
Vol 2019 ◽  
pp. 1-3
Author(s):  
James Nguyen ◽  
Amani Jambhekar ◽  
Ziyad Nasrawi ◽  
Prasad Gudavalli

Introduction. In patients who have undergone resection for rectal cancer after neoadjuvant radiotherapy, loop ileostomy is commonly performed with few serious complications. In rare cases, if this irradiated small bowel is strictured, reversal of the affected ileostomy can have dire consequences. We present a case of a 62-year-old male with recurrent intestinal obstruction after closure of his loop ileostomy. Case Report. RC is a 62-year-old male who initially presented with rectal cancer and underwent neoadjuvant chemoradiation prior to a laparoscopic low anterior resection with diverting loop ileostomy. He underwent elective reversal of his ileostomy and developed persistent postoperative obstruction. He underwent resection of the prior reversal site with normal-appearing dilated proximal bowel loops and collapsed distal bowel loops. He again developed an obstructive picture and underwent resection of the prior anastomosis with creation of an ileocolic anastomosis, after which he recovered well postoperatively. Conclusion. In patients who receive radiation adjuvant therapy for colon cancer, radiation-induced stricture should be considered as a cause of small bowel obstruction postoperative. In the setting of a longstanding ileostomy, evaluation of a defunctionalized distal ileum may be necessary to evaluate potential obstruction from radiation changes.

2019 ◽  
Vol 1 (2) ◽  
pp. 01-03
Author(s):  
Ifeanyi Umoke

Reports have revealed the existence of colonic cancer with chronic bowel schistosomiasis. The specie most frequently involved is Schistosoma japonicum. Few cases have, however, shown Schistosoma mansoni as the involved specie. There seems to be an association between rectal cancer and Schistosoma mansoni infestation. Despite earlier studies that refuted any association between schistosomiasis and colonic cancer, more reports are lending credence to the claim that chronic colonic schistosomiasis, especially with S. Japonicum, may induce colonic cancer and the case with are reporting also point to the fact that S. Mansoni may also be implicated. We report a case of a 35-year-old man with a rectal cancer (pT3N0M0) associated with Schistosoma mansoni. He presented with intestinal obstruction and operation revealed a cirrhotic liver with hepatic schistosomiasis.


2020 ◽  
Author(s):  
Shun Wong ◽  
William Chu ◽  
Shady Ashamalla ◽  
Darlene Fenech ◽  
Scott Berry ◽  
...  

Abstract Background: Neoadjuvant radiotherapy with or without chemotherapy decreases the risk of local recurrence after surgery for stage II or III rectal cancer. Emerging data suggest that diabetic patients on metformin may have improved cancer outcome after radiotherapy. We asked if metformin given concurrently with long course chemoradiation (CRT) may improve pathologic complete response (pCR) in non-diabetic rectal cancer patients. A single-institutional pilot study was performed to build a confidence interval for the pCR rate and to determine the sample size for a phase 2 trial.Methods: Non-diabetic patients with biopsy confirmed adenocarcinoma of the rectum, and deemed candidates for long course neoadjuvant CRT were invited to participate. Radiation consisted of 50.4 Gy in 28 daily fractions. Capecitabine (825 mg/m2 twice daily, Monday-Friday) was self-administered during the 28 days of radiation only. The primary outcome was pCR. The study was designed to accrue 15 participants to construct a confidence interval (CI) for the pCR rate. Results: A total of 16 patients were accrued from January 2017 to May 2018. One patient withdrew from the study prior to CRT. Only grade 1 or 2 adverse events were observed from the intervention. Three patients had a clinical complete response (cCR) and did not have surgical resection. Of the 12 patients who underwent surgery, there were two pCRs. For the combined pCR/cCR rate of 33% (95% CI 19-47%), a total of 85 patients will be required to yield a 95% CI with a 10% margin of error. Conclusions: Adding metformin to neoadjuvant CRT for rectal cancer does not appear to enhance toxicities. These results will be used to refine the design and conduct of a future phase 2 trial to determine whether adding metformin to CRT improves pCR/cCR rates. Trial registration: NCT03053544. Registered December 20, 2016, https://clinicaltrials.gov/ct2/show/record/NCT03053544


Sign in / Sign up

Export Citation Format

Share Document